We can offer a discount on bulk orders. Please contact our sales team for further inquiry.
Product Infomation
Product Name DOX-SAA@LNP-DTPA, doxorubicin-SAA modified lipid nanoparticles-DTPA complex
Catalog Number R-LNP2
Alias Doxorubicin-serum amyloid A modified lipid nanoparticles-diethylenetriaminepentaacetic acid complex,
Appearance Dispersion
Molecular Formula N/A
Solubility Can be stably dispersed in aqueous solution to form a colloidal system
Storage 2-8°C, protected from light
Purity 95%+
Shelf Life 1 year
Shipping Condition low temperature transport
Application MRI contrast agent
Specification 10mg：Inquiry
20mg：Inquiry
50mg：Inquiry
Description DOX-SAA@LNP-DTPA is a nanocomposite that integrates drug delivery, targeted transport and imaging diagnosis functions. The complex uses lipid nanoparticles (LNP) as the core carrier. With its good biocompatibility and degradability, it can efficiently encapsulate doxorubicin, effectively protect the drug activity and reduce the side effects of the drug on normal tissues. Serum amyloid A (SAA) is modified on the surface of LNP, which can specifically recognize receptors abnormally expressed on the surface of tumor cells, giving the complex the ability to actively target tumor cells, allowing doxorubicin to be accurately enriched in the tumor site. The introduction of diethylenetriaminepentacetic acid (DTPA) can not only chelate metal ions and serve as a magnetic resonance imaging (MRI) contrast agent to achieve visual diagnosis of tumor, but can also adjust the surface properties of nanoparticles and optimize their in vivo circulation performance.
Online Inquiry
For Research or Industrial Raw Materials, Not For Personal Medical Use!
Place the Order
FAQs
logo

Enter your email here to subscribe.

Copyright © MATEXCEL. All Rights Reserved.
0
Inquiry Basket